Airway mucus plugging is a life-threatening feature of acute asthma exacerbations, and no treatments can effectively hasten plug removal. Normal airway mucus gel is lightly cross-linked and fluid, whereas mucus casts in acute asthma are densely cross-linked and semi-solid. How these cross-links arise is poorly understood, but may involve as yet unidentified cross-linking proteins. We hypothesize that mucin polymers are cross-linked by endogenous multimeric lectins specific for galactosyl residues in their O-linked glycans. Our preliminary data includes evidence that: (i) galectin-3 (Gal-3) and intelectin-1 (ITLN-1) are multimeric lectins capable of cross-linking mucins;(ii) these proteins are present in the airway mucus of acute severe asthmatic and are protease sensitive;(iii) galactose, but not glucose, can compete with these lectins to decrease airway mucus cross-linking. We propose three Aims to further explore the mechanisms of mucus gel formation and turnover in health and in acute asthma and to identify the mucolytic potential of galactosyl sugars.
In Aim 1 we will determine if Gal-3 and ITLN-1 increase mucin cross-linking, and if assembly of normal airway mucus gels requires these lectins.
In Aim 2 we will test if galactosyl sugars competing off lectin the binding to mucins to decrease mucu elasticity. We will screen a library of glycomimetic carbohydrates for their ability to prevent mucin lectin binding and to act as mucolytics. We will also profile mucin glycans for the natural glcyan receptors for GAL-3 and ITLN-1.
In Aim 3 we will focus on studies of airway mucus collected from asthmatic subjects in acute exacerbation. We will determine if GAL-3 and ITLN-1 are components of pathologic mucus in asthma exacerbations, explore the clinical and inflammatory correlates of different lectin profiles, and probe for lectin degradation products in mucus collected during asthma recovery. As in Aim 2, we will determine the effect of mucolytic sugars on the elastic modulus of asthmatic sputum, and we will explore if the natural glycan binding parnters for GAL-3 and ITLN1 are similar in asthma as in health. These studies address an important clinical problem with unmet therapeutic needs, use a multidisciplinary approach, and hold promise to reveal novel mucoltyic therapies for asthma.

Public Health Relevance

This project aims to uncover mechanism of mucus gel formation in health and in acute asthma with a view toward the development of novel mucolytic therapies for acute asthma. Our preliminary studies have uncovered a novel mechanism of mucin cross-linking via multimeric lectins interacting with mucin glycans, a mechanism that provides a rationale for the use of specific carbohydrate structures as novel therapeutic agents for acute asthma.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL080414-07
Application #
8453398
Study Section
Lung Cellular, Molecular, and Immunobiology Study Section (LCMI)
Program Officer
Noel, Patricia
Project Start
2005-07-01
Project End
2015-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
7
Fiscal Year
2013
Total Cost
$489,635
Indirect Cost
$141,492
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Lachowicz-Scroggins, Marrah E; Yuan, Shaopeng; Kerr, Sheena C et al. (2016) Abnormalities in MUC5AC and MUC5B Protein in Airway Mucus in Asthma. Am J Respir Crit Care Med 194:1296-1299
Peters, Michael C; McGrath, Kelly Wong; Hawkins, Gregory A et al. (2016) Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med 4:574-84
Fahy, John V (2016) Asthma Was Talking, But We Weren't Listening. Missed or Ignored Signals That Have Slowed Treatment Progress. Ann Am Thorac Soc 13 Suppl 1:S78-82
Kerr, Sheena C; Fischer, Gregory J; Sinha, Meenal et al. (2016) FleA Expression in Aspergillus fumigatus Is Recognized by Fucosylated Structures on Mucins and Macrophages to Prevent Lung Infection. PLoS Pathog 12:e1005555
Yuan, Shaopeng; Hollinger, Martin; Lachowicz-Scroggins, Marrah E et al. (2015) Oxidation increases mucin polymer cross-links to stiffen airway mucus gels. Sci Transl Med 7:276ra27
Dunican, Eleanor M; Fahy, John V (2015) The Role of Type 2 Inflammation in the Pathogenesis of Asthma Exacerbations. Ann Am Thorac Soc 12 Suppl 2:S144-9
Kerr, Sheena C; Carrington, Stephen D; Oscarson, Stefan et al. (2014) Intelectin-1 is a prominent protein constituent of pathologic mucus associated with eosinophilic airway inflammation in asthma. Am J Respir Crit Care Med 189:1005-7
Peters, Michael C; Mekonnen, Zesemayat K; Yuan, Shaopeng et al. (2014) Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol 133:388-94
Jackson, Daniel J; Hartert, Tina V; Martinez, Fernando D et al. (2014) Asthma: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc 11 Suppl 3:S139-45
Houser, Josef; Komarek, Jan; Kostlanova, Nikola et al. (2013) A soluble fucose-specific lectin from Aspergillus fumigatus conidia--structure, specificity and possible role in fungal pathogenicity. PLoS One 8:e83077

Showing the most recent 10 out of 27 publications